Iscalimab
As of the edition of 20 October 2026, Iscalimab is an antibody: stopped in 2023; acts on CD40.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Antibody
- Registered trials
- 11, 1 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Eye; Mouth and teeth; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Iscalimab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD40 | Tumor necrosis factor receptor superfamily member 5 | P25942 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 10 | 8 | 1 | 1 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2013 to now |